Long-term survival and late deaths after allogeneic hematopoietic cell transplantation, J Clin Oncol, vol.29, issue.16, pp.2230-2239, 2011. ,
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation, J Clin Oncol, vol.28, issue.6, pp.1011-1017, 2010. ,
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia, Blood Adv, vol.4, issue.6, pp.983-92, 2020. ,
Pathophysiology of chronic graft-versus-host disease and therapeutic targets, N Engl J Med, vol.377, issue.26, pp.2565-79, 2017. ,
Acute graft-versus-host disease -biologic process, prevention, and therapy, N Engl J Med, vol.377, issue.22, pp.2167-79, 2017. ,
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation, Lancet Haematol, vol.7, issue.2, pp.157-67, 2020. ,
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, vol.10, issue.9, pp.855-64, 2009. ,
Longterm outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial, Lancet Haematol, vol.4, issue.6, pp.293-301, 2017. ,
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial, Lancet Oncol, vol.17, issue.2, pp.164-73, 2016. ,
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, vol.98, issue.10, pp.2942-2949, 2001. ,
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Blood, vol.117, issue.25, pp.6963-70, 2011. ,
Unrelated Donor Marrow Transplantation T. Effect of graft-versus-host disease prophylaxis on 3-year diseasefree survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial, Lancet, vol.366, issue.9487, pp.733-774, 2005. ,
Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond, Leukemia, vol.21, issue.7, pp.1387-94, 2007. ,
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, vol.14, issue.6, pp.641-50, 2008. ,
T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLAmatched related and unrelated donor transplantation, J Clin Oncol, vol.31, issue.10, pp.1310-1316, 2013. ,
Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide, J Exp Med, vol.169, issue.1, pp.213-251, 1989. ,
Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion, J Immunol, vol.145, issue.5, pp.1303-1313, 1990. ,
Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice, Blood, vol.124, issue.13, pp.2131-2172, 2014. ,
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide, Sci Transl Med, vol.5, issue.211, pp.211-157, 2013. ,
Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression, J Clin Invest, vol.129, issue.6, pp.2357-73, 2019. ,
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation, Blood, vol.127, issue.11, pp.1502-1510, 2016. ,
Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors, Biol Blood Marrow Transplant, vol.23, issue.3, pp.459-66, 2017. ,
Single antigen-mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable alternative for patients lacking HLA-matched donors, Biol Blood Marrow Transplant, vol.24, issue.6, pp.1196-202, 2018. ,
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT, J Hematol Oncol, vol.11, issue.1, p.40, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01762520
Posttransplant cyclophosphamide vs antithymocyte globulin in HLAmismatched unrelated donor transplantation, Blood, vol.134, issue.11, pp.892-901, 2019. ,
, consensus conference on acute GVHD Grading, vol.15, pp.825-833, 1994.
Chronic graft-versus-host disease, Biol Blood Marrow Transplant, vol.9, issue.4, pp.215-248, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00849664
Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation, Clin Hematol Int, vol.2, issue.1, pp.2-4, 2020. ,
Nonparametric estimation from incomplete observations, J Am Stat, vol.53, issue.282, pp.457-81, 2008. ,
Frailty models for survival data, Lifetime data analysis, vol.1, issue.3, pp.255-73, 1995. ,
Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests, Statistics in medicine, vol.18, issue.12, pp.1489-500, 1999. ,
Prospective, randomized, double-blind, phase III clinical trial of anti-Tlymphocyte globulin to assess impact on chronic graft-versus-host diseasefree survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation, J Clin Oncol, vol.35, issue.36, pp.4003-4014, 2017. ,
Antilymphocyte globulin for prevention of chronic graft-versus-host disease, N Engl J Med, vol.374, issue.1, pp.43-53, 2016. ,
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease, Blood, vol.115, issue.16, pp.3224-3254, 2010. ,
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation, Leukemia, vol.25, issue.6, pp.932-940, 2011. ,
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases, Cancer, vol.119, issue.5, pp.986-92, 2013. ,
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Bone Marrow Transplant, vol.49, issue.3, pp.389-96, 2014. ,
The impact of anti-thymocyte globulin on the outcomes of patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation, Leukemia, vol.34, issue.4, pp.1144-53, 2020. ,
Antithymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate-or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission -a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation, Br J Haematol, vol.184, issue.4, pp.643-649, 2019. ,
A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors, Clinical transplantation, vol.27, issue.4, pp.368-74, 2013. ,
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation, Bone Marrow Transplant, vol.53, issue.4, pp.431-438, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02143554
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations